higher proportion of patients with favourable or intermediate IMDC prognostic criteria, better Karnofsky performance status [KPS], etc).
5 months for those who did not (HR adjusted for IMDC prognostic criteria: 0.
The authors concluded that CN may extend overall survival in patients with mRCC, but that patients with 4 or more IMDC factors and limited life expectancy should probably not receive CN.
Another analysis from the IMDC presented at GU-ASCO 2014 sought to validate the IMDC prognostic model in patients with mRCC receiving next-line targeted therapy after progression on first-line targeted therapy, and to compare the IMDC model to the 3-item Memorial Sloan Kettering Cancer Center (MSKCC) second-line prognostic model.
The 6 IMDC prognostic factors are KPS <80%, diagnosis-to-treatment interval of less than 1 year, anemia, hypercalcemia, neutrophilia and thrombocytosis.